John Dang Nguyen

This inventor holds 11 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Reva Medical, Inc., Biotronik Ag. Active years: 2010-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Dang Nguyen. Retrieved from https://idiyas.com/inventor/john-dang-nguyen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 5)

% Patents Active = 36.4

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 3.9

ph-index = 6

Forward Citations = 399(Granted Patents)

Company Filing History:

Years Active: 2010-2022

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11383009 - Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods (2022-07-12),

2. 10751450 - Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods (2020-08-25),

3. 9867911 - Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods (2018-01-16),

4. 9408884 - Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods (2016-08-09),

5. 9173751 - Slide-and-lock stent (2015-11-03),

6. 8617235 - Axially nested slide and lock expandable device (2013-12-31),

7. 8512394 - Balloon expandable crush-recoverable stent device (2013-08-20),

8. 8292944 - Slide-and-lock stent (2012-10-23),

9. 8277500 - Slide-and-lock stent (2012-10-02),

10. 7914574 - Axially nested slide and lock expandable device (2011-03-29),

11. 7763065 - Balloon expandable crush-recoverable stent device (2010-07-27),

Title: The Innovative Contributions of John Dang Nguyen

Introduction

John Dang Nguyen is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of pharmaceuticals. With a total of 11 patents to his name, Nguyen has made remarkable advancements in drug formulations and therapeutic methods.

Latest Patents

Nguyen's latest patents include the development of rapamycin 40-O-cyclic hydrocarbon esters. This new class of compounds features a unique structure where the 40-O position of the rapamycin ester is represented as 40-O—R. In this formula, R is C(O)—(CH)—X, where n can be 0, 1, or 2, and X is a cyclic hydrocarbon containing 3-8 carbons. These compounds may also include unsaturated bonds and various carbon atoms that can possess an OH or halide group. Additionally, therapeutic compositions and methods utilizing these novel analogs have been disclosed, showcasing Nguyen's innovative approach to drug development.

Career Highlights

Throughout his career, John Dang Nguyen has worked with notable companies such as Reva Medical, Inc. and Biotronik AG. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking advancements in medical technology and pharmaceuticals.

Collaborations

Nguyen has collaborated with esteemed colleagues, including Eric V Schmid and Andrew Morris. These partnerships have further enhanced his research and development efforts, leading to significant innovations in his field.

Conclusion

John Dang Nguyen's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in the development of rapamycin analogs, highlight his commitment to advancing medical science. His career continues to inspire future inventors and researchers in the field.

Profile summary based on public USPTO records.